G1 Therapeutics, Inc.
NASDAQ:GTHX
Overview | Financials
 | Company Name | G1 Therapeutics, Inc. | 
| Symbol | GTHX | 
| Currency | USD | 
| Price | 7.16 | 
| Market Cap    |  377,748,712 | 
| Dividend Yield    |  0% | 
| 52-week-range | 1.08 - 7.19 | 
| Industry | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. John E. Bailey Jr. | 
| Website | https://www.g1therapeutics.com | 
An error occurred while fetching data.
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive 
 Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







